Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab monthly 80 mg versus placebo and versus every-other-week 40 mg in rheumatoid arthritis
2007-005905-23Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Abbott Laboratories. Primary endpoints: ACR20 response at Week 12 versus placebo and Non-inferiority of ACR20 response at Week 12. Started Jan 2008; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-005905-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005905-23.